Argenica Therapeutics Ltd (AU:AGN) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Argenica Therapeutics Ltd has received a positive safety review from the independent Data Safety Monitoring Board for its Phase 2 trial of ARG-007 in stroke patients, with no serious adverse events reported. The trial is progressing well, with 63% of patient dosing completed across activated hospital sites. The company anticipates full dosing completion by mid-2025, with topline data expected shortly after.
For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue